Rhythm Launches IMCIVREE in Japan for Rare Hypothalamic Obesity
Rhythm Pharmaceuticals has begun selling IMCIVREE in Japan after the country's health ministry approved it for acquired hypothalamic obesity. The therapy is the first approved option there for the condition, and it was added to Japan's national reimbursement list. The approval was supported by a Phase 3 trial that showed an 18.8% placebo-adjusted BMI reduction.
Rhythm Pharmaceuticals has started selling IMCIVREE (setmelanotide) in Japan for acquired hypothalamic obesity. The Ministry of Health, Labour and Welfare approved it in August, and the drug now appears on the National Health Insurance price list. It is the first approved treatment for this condition in Japan.
The pivotal Phase 3 TRANSCEND study enrolled 142 patients, including 12 from Japan and 10 supplemental participants beyond the main 120-person group. It met its primary endpoint with an 18.8% BMI reduction after adjusting for placebo. Japanese regulators also granted orphan drug designation; Rhythm estimates 5,000–8,000 people in Japan have acquired HO.
For Japanese patients with acquired hypothalamic obesity, the launch may provide the first approved drug option and possible reimbursement, potentially easing access and disease management. Families and clinicians could gain a new treatment pathway where none existed. Wider impact may be modest given the rare patient population, but it could encourage further rare-disease development and highlight the role of national reimbursement in bringing specialized therapies to small groups.